Dynavax Technologies Co. (NASDAQ:DVAX) Short Interest Update

Dynavax Technologies Co. (NASDAQ:DVAX) was the target of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 21,000,000 shares, a growth of 11.5% from the October 31st total of 18,840,000 shares. Based on an average daily volume of 2,290,000 shares, the days-to-cover ratio is presently 9.2 days.

Analyst Upgrades and Downgrades

DVAX has been the subject of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a research report on Friday, November 8th. The Goldman Sachs Group cut their price target on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th.

Institutional Trading of Dynavax Technologies

A number of large investors have recently modified their holdings of the business. Franklin Resources Inc. lifted its position in Dynavax Technologies by 5.7% in the third quarter. Franklin Resources Inc. now owns 82,415 shares of the biopharmaceutical company’s stock valued at $862,000 after purchasing an additional 4,459 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Dynavax Technologies in the third quarter valued at approximately $89,000. Sanctuary Advisors LLC lifted its position in Dynavax Technologies by 9.1% in the third quarter. Sanctuary Advisors LLC now owns 17,727 shares of the biopharmaceutical company’s stock valued at $197,000 after purchasing an additional 1,484 shares during the last quarter. SkyView Investment Advisors LLC bought a new position in shares of Dynavax Technologies during the third quarter valued at approximately $127,000. Finally, Barclays PLC grew its stake in shares of Dynavax Technologies by 137.4% in the third quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company’s stock worth $3,371,000 after acquiring an additional 175,118 shares during the last quarter. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Trading Down 1.9 %

Shares of Dynavax Technologies stock traded down $0.25 on Tuesday, reaching $12.79. 1,165,635 shares of the company’s stock were exchanged, compared to its average volume of 2,150,743. Dynavax Technologies has a 52 week low of $9.74 and a 52 week high of $15.01. The firm’s 50-day moving average is $11.69 and its two-hundred day moving average is $11.40. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The company has a market capitalization of $1.68 billion, a P/E ratio of 98.39 and a beta of 1.33.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.